Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 3/20 | 0.61 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | EBP | Q15125 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680660 | 0.93 | CALM1 (0.71) | CALM1ATMKDM4ECA2POLB | |
| SCHEMBL623585 | 0.90 | CALM1 (0.57) | CALM1POLBCYP1A2CYP3A4L3MBTL1 | |
| SCHEMBL427541 | 0.88 | ATM (0.68) | ATMKDM4ECA2POLBCYP19A1 | |
| Ammonia Solution, Strong SCHEMBL10556485 | 0.86 | ATM (0.66) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL7089061 | 0.86 | CALM1 (0.58) | CALM1ATMKDM4ECA2POLB | |
| SCHEMBL3125186 | 0.86 | CALM1 (0.58) | CALM1ATMKDM4ECA2POLB | |
| SCHEMBL1223578 | 0.86 | KDM4E (0.77) | CALM1ATMKDM4ECA2POLB | |
| SCHEMBL14586637 | 0.86 | ATM (0.51) | CALM1ATMKDM4ECA2POLB | |
| SCHEMBL11030253 | 0.85 | CALM1 (0.56) | CALM1ATMKDM4ECA2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL8621698 | 0.85 | ATM (0.63) | ATMKDM4ECA2POLBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017105263-A1 | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL AGENT | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2017-06-22 | — | — | WO | disclosed |
| EP-3181549-A1 | PROCESS FOR THE PREPARATION OF APREMILAST | Zaklady Farmaceutyczne Polpharma SA (PL) | 2017-06-21 | — | — | EP | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-7384958-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384958-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7378430-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378430-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070155788-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155788-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070117843-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
| US-20070117843-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155788-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | PDE5A, PDE3A, PDE2A | CALM1 1002/4885ATM 1232/4885KDM4E 1553/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | CALM1 1278/4885ATM 4350/4885KDM4E 3026/4885 |
| US-20070117843-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | CALM1 1002/4885ATM 1232/4885KDM4E 1553/4885 |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | PDE5A, PDE3A, PDE2A | CALM1 1002/4885ATM 1232/4885KDM4E 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.